Attention: Do you have Triple-Negative Breast Cancer?

Participants are Needed for a research study titled “2010-056: A Phase II Study of Anti-CD3 x Anti-HER2/neu (Her2Bi) Armed Activated T Cells (ATC) after Neoadjuvant Chemotherapy in Patients with HER2/neu (0-2+)-Negative Stage II-III Breast Cancers”

**AIM:** To treat women with stage II-III triple-negative breast cancer who have residual disease after neoadjuvant chemotherapy, surgery, and/or irradiation with targeted killer T-cells

**WHO:** To qualify, you must be:
- 18 years of age or older
- Have breast cancer that requires neoadjuvant chemotherapy, surgery, and/or irradiation treatment
- Still have disease at time of surgery
- Is negative for ER, PR, and HER2 receptors

**WHAT:** Eligible participants will undergo targeted T-Cell infusions of Her2Bi-armed ATC

By infusions of targeted T cells, we hope to prevent the recurrence of breast cancer and determine the side effects of the targeted T cell infusions.

Please Contact: Dr. Lawrence G. Lum, MD, DSc. of The Karmanos Cancer Institute at [luml@karmanos.org](mailto:luml@karmanos.org), 313-576-8326 or Kristie Fields, RN [kfields@karmanos.org](mailto:kfields@karmanos.org), 313-576-8384 to see if you are eligible for this clinical trial.

*Note: This clinical trial is sponsored by the National Cancer Institute (NCI).*